These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

66 related articles for article (PubMed ID: 9372438)

  • 1. Antimicrobial activity of LB20304, a fluoronaphthyridone, tested against anaerobic bacteria.
    Marco F; Barrett MS; Jones RN
    J Antimicrob Chemother; 1997 Oct; 40(4):605-7. PubMed ID: 9372438
    [No Abstract]   [Full Text] [Related]  

  • 2. Antimicrobial activity and spectrum of LB20304, a novel fluoronaphthyridone.
    Cormican MG; Jones RN
    Antimicrob Agents Chemother; 1997 Jan; 41(1):204-11. PubMed ID: 8980783
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro and in vivo evaluations of LB20304, a new fluoronaphthyridone.
    Oh JI; Paek KS; Ahn MJ; Kim MY; Hong CY; Kim IC; Kwak JH
    Antimicrob Agents Chemother; 1996 Jun; 40(6):1564-8. PubMed ID: 8726042
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Activities of gemifloxacin (SB 265805, LB20304) compared to those of other oral antimicrobial agents against unusual anaerobes.
    Goldstein EJ; Citron DM; Vreni Merriam C; Tyrrell K; Warren Y
    Antimicrob Agents Chemother; 1999 Nov; 43(11):2726-30. PubMed ID: 10543754
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro activity of gemifloxacin compared to seven other oral antimicrobial agents against aerobic and anaerobic pathogens isolated from antral sinus puncture specimens from patients with sinusitis.
    Goldstein EJ; Conrads G; Citron DM; Merriam CV; Warren Y; Tyrrell K
    Diagn Microbiol Infect Dis; 2002 Feb; 42(2):113-8. PubMed ID: 11858906
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro activities of gemifloxacin (SB 265805, LB20304) against recent clinical isolates of Chlamydia pneumoniae.
    Roblin PM; Reznik T; Kutlin A; Hammerschlag MR
    Antimicrob Agents Chemother; 1999 Nov; 43(11):2806-7. PubMed ID: 10543770
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative in vitro activities of gemifloxacin, other quinolones, and nonquinolone antimicrobials against obligately anaerobic bacteria.
    Kleinkauf N; Ackermann G; Schaumann R; Rodloff AC
    Antimicrob Agents Chemother; 2001 Jun; 45(6):1896-9. PubMed ID: 11353648
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Review of the in vitro activity of gemifloxacin against gram-positive and gram-negative anaerobic pathogens.
    Goldstein EJ
    J Antimicrob Chemother; 2000 Apr; 45 Suppl 1():55-65. PubMed ID: 10824034
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Methods of measuring susceptibility of anaerobic bacteria to trovafloxacin, including quality control parameters.
    Barry AL; Fuchs PC; Thornsberry C; McLaughlin JC; Jenkins SG; Hardy DJ; Allen SD
    Eur J Clin Microbiol Infect Dis; 1996 Aug; 15(8):676-8. PubMed ID: 8894579
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative in vitro activities of trovafloxacin (CP-99,219) against 221 aerobic and 217 anaerobic bacteria isolated from patients with intra-abdominal infections.
    Citron DM; Appleman MD
    Antimicrob Agents Chemother; 1997 Oct; 41(10):2312-6. PubMed ID: 9333074
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The in-vitro activity of trovafloxacin and nine other antimicrobials against 413 anaerobic bacteria.
    Bowker KE; Wootton M; Holt HA; Reeves DS; MacGowan AP
    J Antimicrob Chemother; 1996 Aug; 38(2):271-81. PubMed ID: 8877542
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro susceptibility of Neisseria meningitidis isolates to gemifloxacin and ten other antimicrobial agents.
    Vázquez JA; Berrón S; Giménez MJ; de la Fuente L; Aguilar L
    Eur J Clin Microbiol Infect Dis; 2001 Feb; 20(2):150-1. PubMed ID: 11305475
    [No Abstract]   [Full Text] [Related]  

  • 13. In vitro activity of gemifloxacin against Helicobacter pylori.
    Minehart HW; Chalker AF
    J Antimicrob Chemother; 2001 Mar; 47(3):360-1. PubMed ID: 11222574
    [No Abstract]   [Full Text] [Related]  

  • 14. In-vitro activity of clinafloxacin (CI-960) and PD 131628-2 against anaerobic bacteria.
    Wexler HM; Molitoris E; Reeves D; Finegold SM
    J Antimicrob Chemother; 1994 Oct; 34(4):579-84. PubMed ID: 7868409
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro activity of gemifloxacin and five other fluoroquinolones against defined isogenic mutants of Escherichia coli, Pseudomonas aeruginosa and Staphylococcus aureus.
    Schulte A; Heisig P
    J Antimicrob Chemother; 2000 Dec; 46(6):1037-8. PubMed ID: 11102429
    [No Abstract]   [Full Text] [Related]  

  • 16. The in-vitro activity of tosufloxacin, a new fluorinated quinolone, compared with that of ciprofloxacin and temafloxacin.
    King A; Bethune L; Phillips I
    J Antimicrob Chemother; 1991 Nov; 28(5):719-25. PubMed ID: 1663930
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Methods for testing the susceptibility of anaerobic bacteria to two fluoroquinolone compounds, PD 131628 and clinafloxacin.
    Barry AL; Fuchs PC; Citron DM; Allen SD; Wexler HM
    J Antimicrob Chemother; 1993 Jun; 31(6):893-900. PubMed ID: 8395494
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development of in vitro susceptibility testing methods for gemifloxacin (formerly LB20304a or SB-265805), an investigational fluoronaphthyridone.
    Jones RN; Erwin ME; Biedenbach DJ; Johnson DM; Pfaller MA
    Diagn Microbiol Infect Dis; 1999 Nov; 35(3):227-34. PubMed ID: 10626134
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Urine bactericidal activity after administration of gemifloxacin and trovafloxacin single doses in a phase I study.
    García-Calvo G; Parra A; Ponte C; Soriano F; Giménez MJ; Aguilar L
    Int J Antimicrob Agents; 2002 Dec; 20(6):477-80. PubMed ID: 12458147
    [No Abstract]   [Full Text] [Related]  

  • 20. In vitro and in vivo antibacterial activities of DW-224a, a new fluoronaphthyridone.
    Park HS; Kim HJ; Seol MJ; Choi DR; Choi EC; Kwak JH
    Antimicrob Agents Chemother; 2006 Jun; 50(6):2261-4. PubMed ID: 16723601
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.